Read-only by design — Olmem never buys, sells, shorts, or places any order. This platform provides market research and decision-support tools only. It does not provide personalized financial advice, does not guarantee investment results, and does not execute trades. All investment decisions are the responsibility of the user.
O
← Scanner

BMYBristol-Myers Squibb Company

Healthcare·Drug Manufacturers—General·NYSE·Mkt cap $100.00B
$59.36
$1.79 (+3.11%) today
IEX feed · not consolidated
Last updated Jul 14, 10:11 AM
64/100 Opportunity
26Risk
76Momentum
66Pullback
65Quality
68Valuation
90Trend
Price & History (up to 5 years)
→
Low 0.00— support · — resistanceHigh 0.00
Technical Indicators
RSI (14)60.5
MACD hist0.34
ATR (14)1.40
SMA 2056.32
SMA 5056.34
SMA 20053.23
Rel volume0.9x
Boll upper59.48
Boll lower53.16
52w high61.52
52w low41.01
5y high68.93
5y low35.80
Hist. vol28%
Max drawdown-12%
Long-Term UptrendStrong Momentum WatchPossible Dip BuyEntry: Pullback Watch
Company QualityStable
Revenue growth+8.0%
Earnings growth+10.0%
Profit margin+16.0%
ROE+20.0%
Debt/Equity0.60
Free cash flow—
P/E22.0
Fwd P/E18.0
P/S4.0
P/B4.5
Div yield+1.5%

Bristol-Myers Squibb Company — Drug Manufacturers—General company in the Healthcare sector.

Decision SummaryInternal Rule-Based Analysis
Current Rating
Neutral / Needs Confirmation
Opportunity Score
64/100
Risk Level
Low-Moderate
Best Action
Add to watchlist and monitor for confirmation

Why: BMY is up 3.1% with volume 0.9x its average. Overall, the company is reasonably solid. The long-term trend remains up. Price is holding above key moving averages with constructive structure. This may be worth monitoring, but confirmation is needed before acting.

What to watch: Volume confirmation, hold of nearest support, next earnings date, sector strength, and news sentiment.

Avoid if: Price breaks below support on heavy volume or company guidance weakens.

Internal Rule-Based Analysis · Learning From Historical Outcomes. This rating comes from Olmem’s internal scoring and historical pattern tracking. It is not a guaranteed prediction.

Research only — not financial advice. Olmem never executes trades.

All Scores
Company Quality65
Historical Context50
Valuation68
Trend90
Momentum76
Pullback66
News Sentiment50
Business Move50
Sector Strength55
Risk/Reward41
Entry Timing55
Sell Risk20
Risk26

News & business-move scores come from Olmem’s rule-based news engine (keyword-classified headlines) — no AI. They default to a neutral 50 when there is no recent news.

Recent NewsLive headlines

Real headlines from across the web. By default Olmem reads them with its rule-based news engine (keyword-classified — no AI) to set the News Sentiment score. Connect your own AI provider to have it read these actual headlines in the AI Stock Explanation.